Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - EPIRUS Biopharmaceuticals, Inc. | a14-21307_1ex99d1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): September 23, 2014
EPIRUS BIOPHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in its Charter)
|
Delaware |
|
000-51171 |
|
04-3514457 |
|
(State or Other Jurisdiction of Incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
699 Boylston Street
Eighth Floor
Boston, MA 02116
(Address of Principal Executive Offices) (Zip Code)
Registrant’s telephone number, including area code: (617) 600-4313
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On September 23, 2014, EPIRUS Biopharmaceuticals, Inc. (“Epirus”) issued a press release announcing positive 58 week follow up data from its BOW015 efficacy and safety trial. The full text of Epirus’ press release regarding the announcement is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit |
|
Description |
|
|
|
|
|
99.1 |
|
Press release of EPIRUS Biopharmaceuticals, Inc. dated September 23, 2014 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
EPIRUS BIOPHARMACEUTICALS, INC. | |
|
|
| |
|
|
By: |
/s/ Amit Munshi |
|
|
Name: Amit Munshi | |
|
|
Title: President and Chief Executive Officer | |
Date: September 23, 2014
|
Exhibit |
|
Description |
|
|
|
|
|
99.1 |
|
Press release of EPIRUS Biopharmaceuticals, Inc. dated September 23, 2014 |